CBAY vs. COGT, KURA, EQRX, INVA, ELVN, ANIP, QURE, SAVA, MOR, and LYEL
Should you be buying CymaBay Therapeutics stock or one of its competitors? The main competitors of CymaBay Therapeutics include Cogent Biosciences (COGT), Kura Oncology (KURA), EQRx (EQRX), Innoviva (INVA), Enliven Therapeutics (ELVN), ANI Pharmaceuticals (ANIP), uniQure (QURE), Cassava Sciences (SAVA), MorphoSys (MOR), and Lyell Immunopharma (LYEL). These companies are all part of the "pharmaceutical preparations" industry.
CymaBay Therapeutics vs.
CymaBay Therapeutics (NASDAQ:CBAY) and Cogent Biosciences (NASDAQ:COGT) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, dividends, analyst recommendations, profitability, valuation, community ranking, risk, earnings and media sentiment.
CymaBay Therapeutics presently has a consensus target price of $14.57, suggesting a potential upside of 56.51%. Cogent Biosciences has a consensus target price of $22.50, suggesting a potential upside of 95.65%. Given Cogent Biosciences' higher probable upside, analysts clearly believe Cogent Biosciences is more favorable than CymaBay Therapeutics.
CymaBay Therapeutics has a beta of 0.27, meaning that its share price is 73% less volatile than the S&P 500. Comparatively, Cogent Biosciences has a beta of 1.7, meaning that its share price is 70% more volatile than the S&P 500.
In the previous week, Cogent Biosciences had 6 more articles in the media than CymaBay Therapeutics. MarketBeat recorded 10 mentions for Cogent Biosciences and 4 mentions for CymaBay Therapeutics. CymaBay Therapeutics' average media sentiment score of 1.30 beat Cogent Biosciences' score of 0.86 indicating that CymaBay Therapeutics is being referred to more favorably in the media.
CymaBay Therapeutics has higher earnings, but lower revenue than Cogent Biosciences. CymaBay Therapeutics is trading at a lower price-to-earnings ratio than Cogent Biosciences, indicating that it is currently the more affordable of the two stocks.
73.5% of CymaBay Therapeutics shares are owned by institutional investors. 5.6% of CymaBay Therapeutics shares are owned by insiders. Comparatively, 5.1% of Cogent Biosciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Cogent Biosciences' return on equity of -72.00% beat CymaBay Therapeutics' return on equity.
CymaBay Therapeutics received 227 more outperform votes than Cogent Biosciences when rated by MarketBeat users. Likewise, 72.56% of users gave CymaBay Therapeutics an outperform vote while only 70.22% of users gave Cogent Biosciences an outperform vote.
Summary
CymaBay Therapeutics beats Cogent Biosciences on 10 of the 17 factors compared between the two stocks.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding CBAY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
CymaBay Therapeutics Competitors List
Related Companies and Tools
